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Abstract 
Introduction: The SARS-CoV-2 coronavirus induced infection (COVID-19) can be associated 
with a coagulopathy mainly responsible for pulmonary microvasculature thrombosis and systemic 
thromboembolic manifestations. The pathophysiology and management of the COVID-19 
coagulopathy are likely more complex in patients with inherited bleeding diseases such as 
haemophilia. These individuals might indeed present with both bleeding and thrombotic 
complications and require simultaneous antithrombotic and haemostatic treatments.  
Objective: We propose practical guidance for the diagnosis and management of COVID-19 
coagulopathy in persons with haemophilia.  
Results: Continuation of regular haemostatic treatment is recommended for ambulatory patients. 
For patients requiring hospital admission and on replacement therapy with factors VIII or IX 
concentrates, prophylaxis with concentrates should be intensified according to the risk of bleeding 
complications and associated with prophylactic doses of LMWH. For patients on non-replacement 
therapy, emicizumab should be continued and possibly combined with factor VIII and prophylactic 
doses of LMWH depending on the risk of bleeding and thrombosis. Dose escalation of LMWH 
tailored to the risk of thrombosis can be employed but not supported by evidence. 
Conclusions: These practical recommendations are based on the current literature on COVID-19 
with its impact on haemostasis, indications and modalities for thromboprophylaxis mainly in non-
haemophilic patients and how that is likely to affect persons with haemophilia in different 
circumstances. They will need to be tailored to each patient’s clinical status and validated in future 
studies. 
 
Word count: 222 
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Introduction 
The coronavirus disease 2019 (COVID-19) caused by the novel coronavirus (SARS-CoV-2) is 
continuing its spread globally [1]. Given the absence of prior immunity to this viral infection, it is 
to be expected that persons with haemophilia (PWHs) will be impacted by this illness [2]. Indeed, 
the global haemophilia community is dealing with new challenges to ensuring continued access to 
haemophilia treatments including maintenance of product supply chains, impact of reduced blood 
and plasma donations, reduced access to health care facilities and hemophilia treatment centers, 
postponement of elective surgeries, and negative impacts to clinical research programs. In 
addition, the cancellation of many in person educational and research exchanges risks 
compromising the advancement and dissemination of important knowledge about the care of 
haemophilia and, in particular, guidance on the management of complications from COVID-19 
[2]. 
 
To date, there is a paucity of publications on the clinical experience of PWHs and COVID-19 [3-
7]. There is no information to suggest that PWHs, including those on prophylaxis with traditional 
replacement therapy or emicizumab, are at increased risk for infection or for more severe disease 
unless they have additional well-described co-morbidities such as older age (>65 years), 
pulmonary or cardiovascular disease, hypertension, obesity or diabetes mellitus.  
 
However, we now have emerging characterization of a COVID-19 associated coagulopathy 
(CAC), whose management requires special consideration in PWHs. While many PWHs will 
develop mild or moderate symptoms of COVID-19, a proportion of those infected go on to exhibit 
severe inflammatory responses associated with acute lung injury, hypoxemic respiratory failure 
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and related mortality. Thromboinflammation describes the interplay between inflammation and 
coagulation and is now considered a key driver of this pathology [8-10]. Those with severe 
COVID-19 exhibit coagulation abnormalities including increases in procoagulant levels 
(especially factor VIII, von Willebrand factor, fibrinogen) and elevated D-dimer concentrations, a 
well-characterized biomarker for thrombotic complications [11]. The concomitant presence of this 
CAC at presentation and progression over the course of hospitalization has been associated with 
worsening respiratory status and higher mortality [12]. Notably, this coagulopathy has some 
features of sepsis-induced coagulopathy/disseminated intravascular coagulopathy (DIC), but the 
hemorrhagic phenotype typical of hyperfibrinolytic consumptive DIC, is rare. Therefore, new 
terminologies have been created to recognize this unique alteration in haemostasis such as CAC. 
 
A common finding is an elevation of the D-dimer concentrations even found in ambulant patients 
with no clinically obvious or investigation supported thrombosis. This elevation seems to be 
mainly secondary to intra-pulmonary microvascular thromboses, a frequent manifestation of CAC, 
initially documented in autopsy studies and more recently in antemortem imaging using the dual 
energy computed tomography (DECT) technology [13-16]. The clinical experience has also 
indicated an increased risk of more common thromboembolic complications in the outpatient 
setting as well as in hospitalized patients with venous thromboembolism, pulmonary emboli, 
ischemic limbs and stroke events [11]. This has prompted consensus guidance on coagulation test 
surveillance, thromboprophylaxis, choice of anticoagulants and intensity of dosing. Though these 
guidelines and recommendations will need to be tested and even adapted based on clinical studies, 
their implementation poses special challenges to PWHs.  
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Previous communication from the WFH COVID-19 Task Force highlighted these coagulation 
abnormalities with COVID-19 and directed attention toward the need for close laboratory 
monitoring, the need for factor replacement therapy to facilitate the use of anticoagulants for 
prophylaxis or treatment, and special considerations for patients on concomitant prophylaxis with 
emicizumab. The current guidance seeks to expand on the prior guidance based on emerging data 
on the mechanisms of thromboinflammation with COVID-19 and current approaches in use for 
the management of hospitalized non-haemophilia patients. We provide consensus 
recommendations on management of hospitalized PWHs with special considerations regarding 
hemostatic correction with concurrent anticoagulation and/or intensive care procedures, and 
updated details regarding management with concurrent use of emicizumab.  
 
Current understanding of mechanisms of thrombo-inflammation with COVID-19 
Review of the emerging data on the mechanisms of thrombo-inflammation with COVID-19 have 
identified the following [11;14]: 
 Exaggerated inflammatory response to the pulmonary alveolar injury characterized by 
procoagulant effectors 
o inflammatory cytokines (eg. IL-6) lead to activation of vascular endothelial cells 
and endothelial injury  
o components of neutrophil extracellular traps (NETs), present in thrombi, activate 
the contact pathway and enhance procoagulant pathways resulting in increased 
thrombin generation 
o polyphosphates activate platelets, mast cells and factor XII in the contact pathway 
amplifying the intrinsic pathway of coagulation 
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o serine protease inhibitors (antithrombin, protein C, C1 esterase inhibitor) are 
decreased 
o fibrinolysis is impaired due to elevated PAI-1 levels [11;14] 
 
Another unique aspect of the pathology of this infection is an endothelialopathy that appears to 
contribute to the microvascular changes that occur with COVID-19 [15;17]. SARS-CoV-2 gains 
access to cells through the angiotensin-converting enzyme (ACE) 2 that is present on endothelial 
cells [18]. Ensuing inflammatory cell infiltration, endothelial cell apoptosis and microvascular 
prothrombotic effects lead to microcirculatory dysfunction and the subsequent clinical sequelae in 
patients with advancing severe disease. 
 
Current approaches for management of hospitalized non-hemophilia patients with 
COVID-19 
Guidance on the recognition, monitoring and management of CAC has been provided from the 
ISTH [19], American Society of Hematology [20], and the American College of Cardiology [21] 
and many others. These recommendations have been taken into account and summarized as 
follows: 
 
Recognition and Monitoring of COVID-19 Associated Coagulopathy  
1. Coagulopathy shows elevated fibrinogen, factor VIII, VWF, elevated D-dimers, with 
minimal change in prothrombin time (PT), activated partial thromboplastin time (aPTT), 
and platelet count in early stages of infection  
2. Increasing IL-6 levels directly stimulate increasing fibrinogen levels  
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3. Coagulopathy appears to be related to severity of illness and resultant 
thromboinflammation and not the intrinsic viral activity  
4. Increased D-dimer is the most significant change in coagulation parameters in COVID-19 
patients and occurs more frequently than disturbances of other coagulation parameters 
(PT, aPTT) 
5. Elevated D-dimer levels on admission are associated with increased mortality  
6. Rising D-dimer after admission precedes multiorgan failure and overt DIC  
a. Noted to start at 4 days after admission in non-survivors  
b. Longer duration of hospital stay is associated with increasing D-dimer and 
development of sepsis physiology  
7. A sudden marked decrease in plasma fibrinogen to concentration less than 1.0 g/L 
suggestive of disseminated intravascular coagulation with enhance fibrinolysis has been 
observed shortly before death in a number of patients with COVID-19 in China [22]. 
8. A significant reduction of the platelet count, fibrinogen or antithrombin levels, most 
frequently associated with DIC, have not been frequently described in patients with 
COVID-19 
9. Bleeding manifestations are not common despite the coagulopathy [19-21;23]. In a recent 
large study, the overall and major bleeding rates were close to 5 and 2 %, respectively 
[23]. 
 
Suggested approaches to COVID-19 patients and coagulopathy.  
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All admitted patients should have baseline coagulation work-up including PT, aPTT, fibrinogen, 
D-dimer, and platelet count. Following changes in these values can give important information 
regarding status of the coagulation system and safety of using anticoagulation (Table 1). Risk for 
thrombosis should be assessed in all patients.  
Several studies have shown among COVID-19 infected ICU patients an increased rate of venous 
thrombo-embolism (VTE) [24;25], the presence of pulmonary microthrombosis and a generalized 
inflammatory response of the endothelium possibly causing fatal organ failure. 
As recommended by recent consensus guidelines, standard weight-based prophylactic 
anticoagulation with low molecular weight heparin (LMWH) should be offered as early as possible 
to prevent thrombotic events and organ damage in all patients with COVID-19 infection requiring 
hospital admission, including the noncritically ill, unless contra-indicated. Anticoagulant options 
include LMWH, unfractionated heparin (UFH) and fondaparinux. Direct oral anticoagulants 
should not be considered because of possible interactions with antiviral therapeutics [21]. LMWH, 
besides their anticoagulant properties, may exert an anti-inflammatory effect and attenuate in part 
the 'cytokine storm' induced by the virus [26]. 
Although the concept of using LMWH in hospitalized COVID-19 patients is accepted, there is a 
debate about the dosage to be employed. Thromboses have been reported despite low-dose 
prophylactic use of LMWH so that dose escalation of LMWH has been recommended either 
empirically or based on increasing D-dimers values.  
Although there is currently limited data supporting that the dosing should be intensified in some 
patients, several national and scientific society guidance documents suggest therapeutic 
COVID-19 coagulopathy and haemophilia Revised Version 2 
 9 
anticoagulation in patients with respiratory compromise and features of CAC particularly if 
associated with highly elevated D-dimer levels based on the data available so far from uncontrolled 
studies showing improved outcomes with such interventions in such patients [27-29]. This 
approach would aim at treating ‘presumed’ microvascular thrombosis as suggested by correlations 
between coagulation markers and pulmonary pathology findings. 
Several randomized control trials evaluating different anticoagulation modalities are ongoing 
including the RAPID COVID COAG trial that aims at determining the effect of therapeutic 
anticoagulation (with LMWH or UFH) compared to standard care in hospitalized patients with 
COVID-19 and an elevated D-dimer on the composite outcome of intensive care unit (ICU) 
admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death at 
28 days [30]. 
While no data specific to COVID-19 exist, it is reasonable to consider extended 
thromboprophylaxis after hospital discharge for selected patients with elevated risk of VTE and 
low risk of bleeding [21]. 
While routine use in outpatients is not recommended, use in immobile infected outpatients, 
especially with other increased risks for VTE, can be considered on a case by case basis based on 
severity of illness or as incorporated into local practice.  
Special considerations for PWHs 
Haemophilia is characterized by a defect in thrombin generation with resultant reduced fibrin 
formation. In the case of haemophilia A, there are also no marked elevations of factor VIII with 
underlying inflammation. Therefore, it is possible that this could blunt the severity of the impact 
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of CAC in persons with both haemophilia A. However, many of the mechanisms described above, 
including the impact of endothelial injury leading to microvascular dysfunction are not solely 
dependent on thrombin generation. Further, the defective thrombin generation in haemophilia is 
modulated by prophylactic therapy with clotting factor concentrates or emicizumab, or can be 
transiently corrected as needed for bleeding, invasive procedures or to facilitate anticoagulation. 
Accordingly, a PWH and a COVID-19 infection with its risk for CAC, poses unique management 
challenges for those requiring admission to the hospital. PWHs with moderate to severe COVID-
19 infection necessitating admission should be transferred to a haemophilia treatment center 
affiliated hospital capable of on-site factor assays as well as other specialized assays like bovine 
chromogenic factor VIII assay if on emicizumab. 
 
The consensus guidance that follows seeks to provide recommendations on considerations for 
recognizing and monitoring for CAC, recommendations for hemostatic correction around invasive 
procedures, anticoagulation and include special considerations for those on emicizumab 
prophylaxis.  
 
Considerations for recognition and monitoring for COVID-19 Associated Coagulopathy in 
PWHs 
1. We recommend using standard laboratory assays for recognition and monitoring for CAC 
with these considerations (Table 2):  
a. The PT, fibrinogen and D-dimer assays are not affected by underlying 
haemophilia or concomitant treatment with clotting factor replacement therapy. 
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b. The aPTT needs to be evaluated in the context of recent replacement therapy and 
is typically within the normal range with most reagents, with factor VIII or IX 
levels above 30-40%. 
c. Patients with mild haemophilia A might display increased or high FVIII levels 
during the inflammatory response of COVID-19. Factor VIII levels should be 
checked prior to start any therapy in mild haemophilia A patients and historical 
levels not trusted. 
d. D-dimer levels are not typically increased in haemophilia except in the context of 
significant concurrent bleeding [31] or patients receiving intensified therapy with 
bypassing agents [32] ). Neither are there reported observations of elevated D-
dimer in patients on prophylaxis with emicizumab (G. Levy, personal 
communication). Therefore, we recommend that D-dimers be measured in all 
patients regardless of their prophylactic therapy upon admission and followed 
regularly during hospital admission and with any clinical deterioration. 
e. The aPTT is highly sensitive to emicizumab and is consistently and erroneously 
within the normal range for patients on all dosing regimens and should not be 
utilized in this context [33]. 
f. When interpreting prolonged aPTT, possible interference with a lupus 
anticoagulant, reported to be associated with COVID-19, should be excluded 
[34;35]. 
2. Standard thromboprophylaxis 
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a. We do not recommend routine thromboprophylaxis in hemophilia regardless of 
prophylactic therapy for those with mild/moderate COVID-19 who are able to be 
managed in the outpatient setting (Table 3). 
b. Thromboprophylaxis should be considered for PWH without inhibitor if their 
COVID-19 illness requires admission to hospital because of respiratory 
insufficiency [as per local institutional/national guidelines] after discussion of the 
bleeding and thrombotic risks with the patient and family. Thromboprophylaxis 
should be associated with replacement therapy targeting factor VIII or IX levels 
sufficient to prevent bleeding complications (spontaneous or related to invasive 
procedures) but not aggravating the risk of thrombosis.  
i. LMWH is preferred over UFH due to the reduced intensity of laboratory 
monitoring for quarantined patients, ease of administration and reduced 
risk of heparin-induced thrombocytopenia. 
ii. We recommend initiating or continuing prophylactic therapy to facilitate 
anticoagulation 
1. For hemophilia A: maintenance of factor VIII activity targeting 
trough levels of at least 30% while avoiding peaks above 100% 
2. For hemophilia B: maintenance of factor IX trough activity levels 
of at least 30%. Avoidance of high peak corrections of factor IX 
above 80% is recommended given the likelihood of markedly 
elevated factor VIII levels in this patient population. 
iii. We do not recommend additional factor VIII replacement therapy for 
patients who are at steady state prophylaxis with emicizumab as there is 
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anecdotal experience supporting that the level of hemostatic protection 
with emicizumab can at least support standard anticoagulation without 
significant bleeding risk [36].  
c. Thromboprophylaxis should be considered for PWHs with inhibitor if on 
emicizumab prophylaxis (Table 4) 
i. We do not recommend regular prophylactic use of bypassing agents in 
order to facilitate anticoagulation for thromboprophylaxis. In particular, 
use of activated prothrombin complex concentrates (aPCC) with 
emicizumab has been associated with cases of thrombotic 
microangiopathy and thrombotic events, therefore the benefit/risk should 
be carefully considered and preferably avoided if at all possible.  
ii. We do not recommend thromboprophylaxis in haemophilia with inhibitor 
for those who are not on emicizumab prophylaxis 
3. Escalated dose thromboprophylaxis or confirmed VTE (Tables 3 and 4) 
a. There is currently no evidence supporting that thromboprophylaxis should be 
intensified for PWHs if they require ICU care and particularly with clinical features 
of acute respiratory distress syndrome or increasing D-dimers concentrations. 
Given the current uncertainty, the decision to escalate thromboprophylaxis should 
be left to local policies until evidence provided by randomized trials appears.  
b. Full dose anticoagulation should be used if confirmed or strongly suspected 
VTE/PE or arterial thrombotic event or when intrapulmonary microvascular 
thromboses have been detected by highly specialized CT angiogram [37]. See 
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below for recommendations for hemostatic prophylaxis to facilitate full dose 
anticoagulation.  
i. LWMH should be preferred over UFH because of its easier once or twice 
daily subcutaneous administration and reduced risk of heparin-induced 
thrombocytopenia. Monitoring should be conducted by anti-Xa assay. 
Dose adaptation is required in patients with renal insufficiency. 
ii. We recommend continuing hemostatic prophylaxis with the following 
considerations: 
1. For hemophilia A: maintenance of factor VIII activity within 50 
and 100 %. 
2. For hemophilia B: maintenance of factor IX activity levels 
between 50 and 80 %. Avoidance of high peak corrections of 
factor IX is recommended given the likelihood of markedly 
elevated factor VIII levels in this patient population. 
3. For hemophilia A on emicizumab: consider addition of factor VIII 
replacement with maintenance of factor VIII activity levels (as 
determined by bovine chromogenic factor VIII assay) of at least 
50-80%. In comparison with emicizumab, factor VIII appears to 
present desirable features for the management of COVID-19 
coagulopathy in persons with haemophilia A (table 5). 
4. There is emerging evidence for thrombotic complications in patients with COVID-19 and 
seemingly milder or absent pulmonary manifestations (“COVID toes”, stroke) even while 
under care in the community. These have not been reported in hemophilia patients to date 
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including those on emicizumab prophylaxis. Although we recommend continued vigilance 
with such symptomatology, there is no basis for which to recommend making changes to 
hemophilia treatment based on these reports. 
 
Considerations for Recognition and Monitoring for COVID-19 Associated Coagulopathy in 
PWHs on Investigational Agents 
There is a number of investigational agents that treat hemophilia by rebalancing hemostasis. These 
include fitusiran (RNA interference knockdown of antithrombin) [38], monoclonal antibodies that 
block tissue factor pathway inhibitor (TFPI) [39;40] and SerpinPC, an engineered serine protein 
inhibitor that targets activated protein C [41]. Some of these agents have moved to phase 3 clinical 
trials, so a number of subjects globally remain at risk for COVID-19 illness. Each of these clinical 
trial programs have a Data and Safety Monitoring Board (DSMB), pharmacovigilance teams, and 
medical monitors that work with the respective investigators to provide advice on management 
that are not covered by the study protocol.  
 
Considering the limited available data on possible interactions between these agents and the 
COVID-19 coagulopathy and the small number of patients on these agents in trials, no valid 
recommendation can here be given on the management of PWHs with COVID-19 on these agents. 
It is the responsibility of the sponsors based on their accumulating data to advise on how to manage 
patients treated with these agents if they get COVID-19. The same recommendations would apply 
to patients in gene therapy trials. 
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Conclusions 
Because of the very limited data in patients with bleeding diseases, these practical 
recommendations are based on our consensus interpretation of the currently available literature on 
the impact of COVID-19 infection on haemostasis in the non-hemophilic population and its 
possible effects in PWHs. These recommendations must be tailored to the specific requirements 
of each patient. They will also need to be tested and validated or modified based on further studies 
and data. To achieve this goal, inclusion of all admitted PWHs with COVID-19 in registries, as 
initiated in many countries, should be strongly encouraged. 
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Tables  
TABLE 1. SUGGESTED APPROACH TO COVID-19 PATIENTS AND COAGULOPATHY 
 
COVID-19 Coagulation tests 
Standard-dose VTE 
prophylaxis 
Escalated-dose 
VTE prophylaxis 
Therapeutic dose  
anti-coagulation 
Outpatient  Consider   
Inpatient X    
Ward X X   
ICU X  
Could be 
considered in the 
absence of evidence 
 
Confirmed VTE X   X 
Presumed PE X   X 
ARDS X  
Could be 
considered in the 
absence of evidence  
 
Adapted from Connors et al. [20] 
 
Table 2. Interpretation and monitoring of blood coagulation parameters of patients with 
COVID-19 coagulopathy 
 Non-haemophilia 
persons 
Persons with haemophilia 
Prothrombin Time Slightly prolonged Slightly prolonged 
aPTT Slightly prolonged Prolonged in HA or HB depending on FVIII 
or FIX deficiency 
Normal if FVIII-FIX level > 30-40 % 
Short in patients on emicizumab 
Interference with a lupus anticoagulant 
should be excluded 
Platelet Count Decreased Decreased 
Fibrinogen Increased Increased 
Decreased in patients with DIC 
D-Dimers Markedly increased Increased according to severity of COVID-
19 coagulopathy  
Not intrinsically affected by haemophilia and 
replacement therapy with FVIII and FIX 
concentrates 
Not affected by emicizumab 
Increase in case of bleed and use of 
Bypassing agents (aPCC)  
aPTT: activated partial thromboplastin time; HA: haemophilia A; HB: haemophilia B; DIC: disseminated 
intravascular coagulation; aPCC: activated prothrombin complex concentrate 
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Table 3. Proposed modalities of substitution with clotting factor concentrates and 
thromboprophylaxis with LMWH in HA and HB patients with COVID-19 coagulopathy 
  
FVIII and FIX substitution 
 
Thromboprophylaxis 
with LMWH 
Outpatient HOME Regular prophylaxis 
None except if 
additional risk factors 
Inpatient 
WARD 
 
FVIII *: maintain > 30 % (trough) while 
avoiding peaks > 100 % 
LMWH 50 IU anti-
Xa/kg OD 
  
FIX *: maintain above 30 % (trough) while 
avoiding peaks > 100 % 
 
 ICU / ARDS FVIII : maintain between 50 and 100 % 
LMWH 50 IU anti-
Xa/kg OD or BD 
  FIX : maintain between 50 and 80 %  
 
PE/DVT 
 
FVIII : maintain between 50 and 100 % 
LMWH 100 IU anti-
Xa/kg BD 
  FIX : maintain between 50 and 80 %  
* If no invasive procedure such as arterial blood gas analysis 
 
 
 
 
 
Table 5. Desirable features of FVIII as haemostatic treatment in haemophilia patients with 
COVID-19 coagulopathy 
Flexibility Rapid onset of action and reversibility 
Measurability and predictability 
FVIII can easily be titrated (APTT/FVIII assays) 
Specific levels can be targeted 
Safety 
 
No or limited risk of thrombosis 
Potential to reduce the risk of thrombosis by maintaining FVIII in the 
normal range (< 100 %) 
Ease of use Monotherapy  
Certainty Known effects on blood coagulation 
 
  
Table 4. Proposed modalities of substitution with EMICIZUMAB/FVIII and 
thromboprophylaxis with LMWH in severe HA patients with COVID-19 
  Haemostatic treatment Thromboprophylaxis with LMWH 
Outpatient HOME Emicizumab alone None except if additional risk factors 
Inpatient WARD Emicizumab alone* LMWH 50 IU anti-Xa/kg OD 
 
ICU / ARDS 
 
Emicizumab + FVIII (50-80 %) LMWH 50 IU anti-Xa/kg OD or BD 
 
PE/DVT 
 
Emicizumab + FVIII (50-80 %) LMWH 100 IU anti-Xa/kg BD 
* If no invasive procedure such as arterial blood gas analysis 
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